Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total revenues | 207,705 | 149,824 |
| Costs and expenses | ||
| Cost of revenues(a) | 23,391 | 15,763 |
| Research and development | 39,438 | 26,927 |
| Selling, general and administrative | 125,173 | 89,944 |
| Amortization of intangible assets | 25,644 | 19,786 |
| Contingent consideration loss | 2,391 | 7,660 |
| Total costs and expenses | 216,037 | 160,080 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's R&D?
- Supernus Pharmaceuticals (SUPN) reported R&D of $39.44M in Q1 2026.
- How has Supernus Pharmaceuticals's R&D changed year-over-year?
- Supernus Pharmaceuticals's R&D increased by 46.5% year-over-year, from $26.93M to $39.44M.
- What is the long-term trend for Supernus Pharmaceuticals's R&D?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's R&D has grown at a 4.1% compound annual growth rate (CAGR), from $90.47M to $106.24M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Supernus Pharmaceuticals's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude